Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.

doi:10.1158/2326-6066.CIR-14-0122

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.

Cancer immunology research - 1 Jan 2015

Acquavella Nicolas, Clever David, Yu Zhiya, Roelke-Parker Melody, Palmer Douglas C, Xi Liqiang, Pflicke Holger, Ji Yun, Gros Alena, Hanada Ken-Ichi, Goldlust Ian S, Mehta Gautam U, Klebanoff Christopher A, Crompton Joseph G, Sukumar Madhusudhanan, Morrow James J, Franco Zulmarie, Gattinoni Luca, Liu Hui, Wang Ena, Marincola Francesco, Stroncek David F, Lee Chyi-Chia R, Raffeld Mark, Bosenberg Marcus W, Roychoudhuri Rahul, Restifo Nicholas P

Abstract excerpt

Both targeted inhibition of oncogenic driver mutations and immune-based therapies show efficacy in treatment of patients with metastatic cancer, but responses can be either short lived or incompletely effective. Oncogene inhibition can augment the efficacy of immune-based therapy, but mechanisms by which these two interventions might cooperate are incompletely resolved. Using a novel transplantable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Indoles

Share to Melanoma

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 25358764
DOI: 10.1158/2326-6066.CIR-14-0122
PMCID: PMC4289107

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.PMID 25358764Read ↗

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.Semantic proximity Read ↗

Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.Semantic proximity Read ↗

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in MelanomaSemantic proximity Read ↗

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.Semantic proximity Read ↗

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond.Semantic proximity Read ↗

MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2Semantic proximity Read ↗

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.Semantic proximity Read ↗

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.Semantic proximity Read ↗

Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD-1 antibody for BRAF-mutated melanoma.Semantic proximity Read ↗

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.Semantic proximity Read ↗

Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?Semantic proximity Read ↗

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.